Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo

Summary

This is a multicenter, randomized, double-blind, vehicle-controlled phase II study of MH004 Ointment with a 28-week open-label long-term safety extension period. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and primary efficacy of MH004 Ointment in adolescents and adults with vitiligo.

Timeline

Start

2024-03-26

Primary completion

2025-09-24

Completion

2026-05-07

Drugs

Indications